As of Jan 10, 2025, United Therapeutics Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $422.5. This suggests it may be undervalued by 15.7% compared to its current price of around $365.0, using a WACC of 7.8% and growth rates of 3.0%.
As of Jan 10, 2025, United Therapeutics Corporation's Weighted Average Cost of Capital (WACC) is approximately 7.8%.
As of Jan 10, 2025, United Therapeutics Corporation's Enterprise Value (EV) is approximately $16.5B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.